• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.

作者信息

Duchemann Boris, Pluvy Johan, Crestani Bruno, Zalcman Gérard, Nunes Hilario

机构信息

Department of Thoracic and Medical Oncology, Avicenne Hospital, AP-HP, Bobigny, France; Université Paris Sorbonne Nord, UFR Santé, Médecine et Biologie Humaine, Bobigny, France.

Department of Thoracic Oncology, Bichat - Claude-Bernard Hospital, AP-HP, Paris, France.

出版信息

Eur J Cancer. 2021 Mar;145:179-182. doi: 10.1016/j.ejca.2020.12.016. Epub 2021 Jan 22.

DOI:10.1016/j.ejca.2020.12.016
PMID:33486441
Abstract
摘要

相似文献

1
Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.肺癌合并特发性肺纤维化患者的免疫检查点阻断治疗
Eur J Cancer. 2021 Mar;145:179-182. doi: 10.1016/j.ejca.2020.12.016. Epub 2021 Jan 22.
2
Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma.一名转移性皮肤汗腺癌患者对抗PD-1治疗的卓越反应。
Eur J Cancer. 2021 Mar;145:143-145. doi: 10.1016/j.ejca.2020.12.015. Epub 2021 Jan 16.
3
Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.PD-1 抑制剂对合并和不合并 COPD 的非小细胞肺癌患者呼出气一氧化氮和肺功能的影响。
Int J Chron Obstruct Pulmon Dis. 2019 Aug 21;14:1867-1877. doi: 10.2147/COPD.S214610. eCollection 2019.
4
Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers.程序性细胞死亡 1 作为上消化道癌症的预后标志物和治疗靶点。
Pathol Res Pract. 2021 Apr;220:153390. doi: 10.1016/j.prp.2021.153390. Epub 2021 Feb 18.
5
Role of immune-checkpoint inhibitors in lung cancer.免疫检查点抑制剂在肺癌中的作用。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075.
6
Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.不同 PD-L1 阳性表达水平的晚期 NSCLC 患者接受 PD-1/PD-L1 抑制剂治疗的有效性和安全性：来自随机对照试验的 4939 例患者的荟萃分析。
Int Immunopharmacol. 2020 Jul;84:106452. doi: 10.1016/j.intimp.2020.106452. Epub 2020 Apr 24.
7
[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].[抗程序性死亡蛋白1治疗期间发生心肌炎时的三度房室传导阻滞：病例报告及文献综述]
Rev Med Interne. 2020 Apr;41(4):284-288. doi: 10.1016/j.revmed.2019.12.023. Epub 2020 Jan 23.
8
Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.癌症免疫检查点抑制剂治疗开始后出现亚急性皮肤型红斑狼疮。
Lupus. 2021 Mar;30(3):531-533. doi: 10.1177/0961203320983448. Epub 2021 Jan 6.
9
Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy.采用抗整合素α4疗法成功治疗严重的抗PD1相关脑膜脑脊髓炎。
Eur J Cancer. 2021 Mar;145:230-233. doi: 10.1016/j.ejca.2020.12.014. Epub 2021 Jan 28.
10
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.SBRT 联合 PD-1/PD-L1 抑制剂治疗 NSCLC：关注机制、进展和未来挑战。
J Hematol Oncol. 2020 Jul 28;13(1):105. doi: 10.1186/s13045-020-00940-z.

引用本文的文献

1
Immune checkpoint inhibitors: From friend to foe.免疫检查点抑制剂：从友到敌。
Toxicol Rep. 2025 Apr 24;14:102033. doi: 10.1016/j.toxrep.2025.102033. eCollection 2025 Jun.
2
Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review.特发性肺纤维化中肺癌的危险因素与管理：一项综述
Sarcoidosis Vasc Diffuse Lung Dis. 2025 Mar 18;42(1):15604. doi: 10.36141/svdld.v42i1.15604.
3
Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease.肺癌合并间质性肺疾病患者的治疗与预后
Cancers (Basel). 2023 Jul 30;15(15):3876. doi: 10.3390/cancers15153876.
4
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.真实世界中晚期非小细胞肺癌合并间质性肺疾病患者接受纳武利尤单抗治疗后的结局
Ther Adv Med Oncol. 2023 Jan 31;15:17588359231152847. doi: 10.1177/17588359231152847. eCollection 2023.
5
[Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia].[免疫相关性肺炎：新型冠状病毒肺炎的鉴别诊断]
Rev Mal Respir. 2022 Sep;39(7):626-632. doi: 10.1016/j.rmr.2022.07.001. Epub 2022 Jul 15.
6
Diagnostic Value of Serum Levels of IL-22, IL-23, and IL-17 for Idiopathic Pulmonary Fibrosis Associated with Lung Cancer.血清白细胞介素-22、白细胞介素-23和白细胞介素-17水平对特发性肺纤维化合并肺癌的诊断价值
Ther Clin Risk Manag. 2022 Apr 19;18:429-437. doi: 10.2147/TCRM.S349185. eCollection 2022.
7
Role of the tumor immune microenvironment in tumor immunotherapy.肿瘤免疫微环境在肿瘤免疫治疗中的作用。
Oncol Lett. 2022 Feb;23(2):53. doi: 10.3892/ol.2021.13171. Epub 2021 Dec 20.
8
Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia.合并间质性肺炎的非小细胞肺癌的当前治疗策略
Cancers (Basel). 2021 Aug 6;13(16):3979. doi: 10.3390/cancers13163979.